

1 **A Novel Human TBCK- Neuronal Cell Model Results in Severe Neurodegeneration and**
2 **Partial Rescue with Mitochondrial Fission Inhibition**

3 Rajesh Angireddy¹, Bhanu Chandra Karisetty⁴, Kaitlin A Katsura^{1,3}, Abdias Díaz^{1,2}, Svathi
4 Murali², Sarina Smith¹, Laura Ohl², Kelly Clark^{1,2}, Andrew V. Kossenkov⁴, Elizabeth J.K.
5 Bhoj^{1*}.

6 ¹Division of Human Genetics, Department of Pediatrics, Children's Hospital of Philadelphia,
7 Philadelphia, Pennsylvania, PA, USA.

8 ²Cell and Molecular Biology Graduate Group, Perelman School of Medicine at the University of
9 Pennsylvania, Philadelphia, PA, USA.

10 ³Department of Orofacial Sciences and Program in Craniofacial Biology, University of
11 California, San Francisco, San Francisco, CA, USA.

12 ⁴The Wistar Institute, 3601 Spruce St., Philadelphia, PA 19104.

13 *Correspondence: Bhoje@chop.edu (E. Bhoj).

14 **Keywords:** Neural progenitor cells, mitochondrial dysfunction, cell cycle, neurons, astrocytes,
15 ferroptosis, neurodegeneration

16

17

18

19

20

21

22

23

24 **Abstract:**

25 Background and Objectives: TBCK syndrome is a rare fatal pediatric neurodegenerative disease
26 caused by biallelic loss-of-function mutations in the *TBCK* gene. Previous studies by our lab and
27 others have implicated mTOR, autophagy, lysosomes, and intracellular mRNA transport, however
28 the exact primary pathologic mechanism is unknown. This gap has prevented the development of
29 targeted therapies.

30 Methods: We employed a human neural progenitor cell line (NPC), ReNcell VM, which can
31 differentiate into neurons and astrocytes, to understand the role of TBCK in mTORC1 activity and
32 neuronal autophagy and cellular mechanisms of pathology. We used shRNA technology to
33 knockdown TBCK in ReNcells.

34 Results: These data showed that loss of TBCK did not inhibit mTORC1 activity in neither NPC
35 nor neurons. Additionally, analysis of eight patient-derived cells and TBCK knock down HeLa
36 cells showed that mTORC1 inhibition is inconsistent across different patients and cell types. We
37 showed that TBCK knockdown in ReNcells affected NPC differentiation to neurons and
38 astrocytes. Specifically, differentiation defects are coupled to cell cycle defects in NPC and
39 increased cell death during differentiation. RNAseq analysis indicated the downregulation of
40 several different neurodevelopmental and differentiation pathways. We observed a higher number
41 of LC3-positive vesicles in the soma and neurites of TBCK knockdown cells. Further, TBCK
42 knockdown altered mitochondrial dynamics and membrane potential in NPC, neurons and
43 astrocytes. We found partial mitochondrial rescue with the mitochondrial fission inhibitor mdivi-
44 1.

45 Discussion: This work outlines a new Human Cell Model for TBCK-related neurodegeneration
46 and the essential role of mitochondrial health and partial rescue with mitochondrial fission
47 inhibitor. This data, along with human neurons and astrocytes, illuminate mechanisms of
48 neurodegeneration and provide a possible novel therapeutic avenue for affected patients.

49

50

51

52

53

54

55

56

57

58

59 Introduction:

60 TBCK Syndrome, clinically classified as Infantile Hypotonia with Psychomotor
61 Retardation and Characteristic Facies type 3 (IHPRF3), [OMIM 616899], is a rare autosomal
62 recessive disorder that affects brain development in children carrying *TBCK* gene mutations^{1, 2, 3}.
63 This incurable degenerative and aggressive disease is characterized by a wide range of pathologies,
64 including but are not limited to brain atrophy, developmental delay, epilepsy, hypotonia, and
65 respiratory failure⁴. Although biallelic *TBCK* mutations are known to have profound implications
66 for brain development, the exact mechanism remains unclear. Understanding this mechanism is
67 essential for developing effective therapies.

68 TBC1 domain-containing-Kinase (TBCK) is a protein encoded by the *TBCK* gene present
69 on chromosome 4 (4q24). The protein contains three different domains: the Protein Kinase domain
70 (PK), Tre-2, Bub2, and Cdc16 domain (TBC), and a Rhodanese homology domain (RHOD). While
71 the functions of kinase domain has been proposed to be catalytically inactive and the rhodanese
72 domain function is unknown, the TBC Rab-GAP domain is predicted to be catalytically active^{5, 6}.
73 TBC domains are evolutionarily conserved from yeast and play an essential role in regulating the
74 activities of small Rab proteins⁷. Rab proteins are critical members of the vesicle trafficking
75 pathway and coordinate multiple stages of vesicle formation, transport, tethering and organelle
76 motility in all cell types⁸. Within the last decade, Rab functionality in neurodevelopment and
77 neurodegeneration have become increasingly apparent^{9, 10}. In addition to vesicle transport, TBCK
78 loss modulates mTORC1 activity in patient-derived fibroblasts^{2, 11}.

79 The mechanistic Target Of Rapamycin (mTOR), a serine/threonine kinase, is a master
80 regulator of brain development in eukaryotic cells. This kinase is responsible for homeostatic
81 functions like protein synthesis, cell proliferation, cell survival, cell migration, and cytoskeleton
82 remodeling¹². mTORC can form two multiprotein complexes: mTORC1 and mTORC2. mTORC1
83 is nutrient- and rapamycin-sensitive and regulates protein synthesis and metabolism. mTORC2 is
84 PI3K- and growth factor-sensitive, but rapamycin-insensitive. The mTORC2 regulates
85 proliferation and autophagy through AKT signaling and also regulates glucose and lipid
86 metabolism^{13, 14, 15}. mTORC1 signaling has been reported to be drastically reduced in cells lacking
87 TBCK fibroblast when they were starved and siRNA knock down in 293T cells¹¹. However, the
88 specific mechanism by which TBCK regulates this pathway is unknown². Despite this, autophagy
89 is one common pathway affected in TBCK patients¹⁶. Accumulation of autophagosomes is
90 associated with poor lysosomal activity. TBCK syndrome is even reported clinically as a
91 lysosomal storage disorder and a neuronal ceroid lipofuscinosis disease^{4, 17}. This clinical
92 classification of NCL reveals a buildup of waste products within cells, resulting in dysfunctional
93 cell death, though the findings varied among autopsy reports. These studies indicate that loss of
94 TBCK affects multiple subcellular organelles and vary by cell type function.

95 Neurons are highly metabolically active, requiring functional mitochondria to satisfy their
96 high energy demands. Any perturbations in mitochondrial function leads to neurodegenerative
97 diseases^{18, 19}. Recent findings suggest mitochondrial dysfunction is a common phenotype in
98 TBCK syndrome¹⁷. In a recent study, TBCK was found to associate with a multi protein complex
99 called FERRY, and this complex play an essential role in mRNA transport for local protein

100 translation. Interestingly, a number of mRNA required for mitochondrial biogenesis was
101 associated with FERRY complex²⁰. Although both mitochondrial and lysosomal defects have been
102 previously reported in TBCK patient-derived fibroblasts, this model cannot mimic the
103 environmental conditions and requirements of the brain. Although one study used NPC cells
104 derived from iPSC and showed that loss of TBCK impaired endoplasmic reticulum-to-Golgi
105 vesicle transport and autophagosome biogenesis and altered cell cycle at NPC, the study lacked
106 isogenic controls²¹. Thus, to understand the role of TBCK in brain function, we used an
107 immortalized human Neuronal Progenitor Cell (NPC) line ReNcell VM. These NPCs can be
108 readily differentiated into cortical neuronal lineages, including cortical neurons and astrocytes.^{22,}
109^{23,24}. We used shRNA to knockdown TBCK to assess different aspects of the NPCs differentiation
110 and neurobiology. Specifically, we investigated TBCK role in neuronal differentiation,
111 transcription, autophagy, and mitochondrial health. Our results confirm an important regulatory
112 role of TBCK in all of these subcellular processes and offers a new perspective on the protein as a
113 master regulator of neuronal homeostasis.

114 **Methods:**

115 **Cell culture**

116 We used 293T, ReNcell VM, Skin fibroblasts, lymphoblasts, and DF-HeLa cells. All cell lines
117 (except ReNcells) were cultured in DMEM supplemented with 10% fetal bovine serum (FBS) at
118 37°C with 5% CO₂. Lymphoblasts were grown as suspension cultures. ReNcells were cultured in
119 N2/B27 medium [DMEM:F12 + Neurobasal medium (1:1 ratio) containing B27 neural cell
120 supplement (Gibco), N2 supplement (Gibco), L-Glutamine (2mM, Gibco), Nonessential amino
121 acids (100µM, Sigma), Insulin (5µg/ml, sigma), betamercaptoethanol (100µM, sigma) and
122 penicillin and streptomycin (100 mM, Gibco)] and expanded on laminin coated (20µg/ml in
123 DMEM/F12 medium) tissue culture plates in the presence of bFGF (20ng/ml, Invitrogen) and EGF
124 (20ng/ml, Sigma), and maintained at 37°C in a CO₂ incubator. Differentiation was carried out
125 using two different protocols using laminin-coated plates. For standard differentiation, cells were
126 expanded to confluency in growth medium over 2–3 days. Differentiation was initiated by
127 changing to medium lacking growth factors and cultured for two more weeks.

128 For the pre-aggregation differentiation protocol to generate dopaminergic neurons²², cell
129 aggregates were made by seeding 30,000 cells on ultralow attachment 96-well plates (Corning; cat
130 no:12-356-721) in growth medium and expanded for 7 days with media change for alternate days.
131 Aggregates were harvested and dissociated by smaller trituration and replated on laminin-coated
132 96-well plates. To generate dopaminergic neurons, N2/B27 medium is supplemented with 1 mM
133 dibutyryl-cAMP (Calbiochem) and 2 ng/ml GDNF (Peprotech) to the differentiation media and
134 cultured for seven more days

135 **Generating stable cell lines**

136 HEK293T cells cultured in 60 mm cell culture dish at 80% confluence were transfected with six
137 different plasmids (pLKO.1-Non-Target shRNA, pLKO.1 TBCK sh1-sh5) obtained from Sigma.
138 shRNA sequences are in Supplementary Table 2. Lentivirus was generated for pLKO.1-Non-
139 Target shRNA, and pLKO.1-TBCK sh5, and concentrated using a kit (Takara; Cat: 631231).

140 ReNcells were transduced with concentrated virus, and stable cells were generated by treating with
141 0.4 $\mu\text{g/ml}$ Puromycin. Further, we serially diluted pLKO.1-TBCK sh5 and Scr-Ctrl transduced
142 cells to achieve a one-cell- per-well of a 96-well plate to obtain single cells clones. Similar
143 strategies were applied to generate TBCK KD single-cell clones for DF-HeLa cells.

144 **RNA sequencing and analysis**

145 Raw reads (FASTQ files) from the RNA sequencing were aligned to the Homo sapiens genome
146 (hg19) using STAR version 2.5.2b²⁵. Gene expression levels were measured using RSEM version
147 1.3.3²⁶. Principal component analysis (PCA) was performed in R to cluster the samples and
148 identify the relationships among the samples. Differential gene expression analysis was performed
149 in R using either DESeq2 version 1.38.3²⁷ or NOISeq version 2.42.0²⁸; DESeq2 was used for
150 groups with replicates (Differentiated samples), and NOISeq was used for groups with no
151 replicates (Proliferation samples). In NOISeq analysis, simulated replicates for each condition with
152 small variability were generated using default parameters from its manual. For DESeq2, genes
153 with an adjusted P value < 0.05 were considered significant, and for NOISeq, genes with a
154 probability value > 0.9 were considered significant. The probability value, suggested by the
155 NOISeq manual, is not equivalent to the $1 - P$ value. Annotation was done using the
156 EnsDb.Hsapiens.v75 version 2.99.0. The overlapping of significant genes was represented using
157 UpSetR version 1.4.0²⁹. Gene set enrichment analysis (GSEA) was done for differentiated samples
158 data on R using fgsea version 1.24.0, considering the Enrichr database
159 (<https://maayanlab.cloud/Enrichr/#libraries>: GO_Biological_Process_2021,
160 GO_Cellular_Component_2021, GO_Molecular_Function_2021, KEGG_2021_Human,
161 Reactome_2022, and MSigDB_Hallmark_2020). The ranked gene list for GSEA analysis was
162 generated by ranking genes using the DESeq2-derived Wald statistic values. Heatmaps with the
163 genes of selected pathways were generated using Complex Heatmap version 2.14.0³⁰. All other
164 plots were constructed using ggplot2 version 3.4.0.

165 **Neurosphere assay**

166 To make equal sized neurospheres, we used AggreWell-800 plates (Stemcell Technologies; Cat:
167 34815). AggreWell plates were rinsed with 500 μl anti-adherence solution and centrifuged at
168 1300xg for 5min to remove air bubbles. The rinsing solution was replaced with 1ml of B2/N27
169 medium with growth factors. Then added 3×10^6 cells/ mL into each well (10,000 cells/microwell),
170 and centrifuged the plate at $100 \times g$ for 3 min to capture cells in the microwells. Cells were
171 incubated at 37°C in a CO₂ incubator for six days with partial medium changes on alternate days
172 (Stem Cell Technologies technical manual). Neurosphere images were taken using an Evos XL
173 Core light microscope at 10X magnification and measured using Image J.

174 **Immunocytochemistry**

175 Cells were fixed in 4% paraformaldehyde, washed three times with ice-cold PBS, permeabilized
176 with 0.1% Triton X-100 for 15 min, and blocked with 5% goat serum in PBS for one hour at 25°C.
177 Cells were incubated with primary antibody overnight at 4°C. After washing with PBSx3, the cells
178 were incubated with Alexa fluor-conjugated secondary antibodies for another hour at 25°C. All
179 antibodies and dilutions are reported in supplementary table 3. After three PBS washes, cells were

180 stained with DAPI and mounted on glass slides using Fluoromount-G™ (ThermoFischer
181 Scientific). For MitoTracker™ Orange CMTMRos staining, cells were treated with 200nM dye
182 for 45min and washed three time with PBS and fixed in 4% PFA. Immunofluorescence was done
183 as mentioned above. Images were taken on Leica-SP8 confocal or Keyence fluorescence
184 microscopes at different magnifications. Fluorescence intensity was calculated using Image-J and
185 expressed as corrected total cell fluorescence (CTCF), calculated by subtracting the integrated
186 density value from the area of the selected cell multiplied by the mean fluorescence of background.

187 **Western blot analysis**

188 Cells were homogenized in RIPA buffer (final concentrations: 50 mM Tris, 150 mM NaCl, 1%
189 Triton-X100, 0.1% SDS, 0.5% sodium deoxycholate, with Complete protease and phosphatase
190 inhibitors (Roche), and samples were then clarified by centrifugation at 10,000g for 10min. Total
191 protein concentration was determined by BCA assay (Thermo Scientific; Cat: 23225), and 10µg
192 of total protein was loaded onto 4–12% NuPAGE Bis-tris gels in MES buffer (Invitrogen;
193 Cat:NP0323). After electrophoresis, proteins were transferred to 0.45 µm PVDF (Thermo
194 Scientific; Cat: 88518). Membranes were blocked with 2% BSA-PBS (for detecting
195 phosphorylated proteins) or 5% milk and incubated with different primary antibodies dissolved in
196 2% BSA-PBS, followed by horseradish-peroxidase-coupled secondary antibodies. Blots were
197 developed with ECL Plus reagents (Thermo Scientific; Cat: 34577) and imaged on the ChemiDoc
198 Imaging System (BioRad). Band intensities were calculated using image J. All antibodies and
199 dilutions are presented in Supplemental Table 3.

200 **Gene expression analysis**

201 Cells were dissolved in TRIzol (Life Technologies; Cat: 15596018), and RNA was isolated using
202 Direct-zol RNA Miniprep Kit (Zymo Research; Cat: R2050) according to the manufacturer's
203 instructions. 1µg of total RNA was reverse-transcribed using SuperScript™ VILO MasterMix
204 (ThermoFischer Scientific; Cat:11755050) according to the manufacturer's protocol. RT-qPCR
205 analysis was performed in Quant studio-3 PCR System using a Power-SYBR Green master mix
206 (Applied Biosystems; Cat:100029284). Primers used in the study are shown in Supplementary
207 Table 2. Relative mRNA levels were calculated using $2^{-\Delta\Delta C_t}$ method using GAPDH as a reference
208 gene.

209 **BrdU assay**

210 Scr-Ctrl and TBCK KD ReNcells cells were seeded on a 24-well plate (3×10^3 cells/well) with
211 12mm PDL coverslips coated with laminin in N2/B27 medium. The next day, 3 µg/ml BrdU
212 (Invitrogen; Cat:00-0103) was added and incubated overnight. For BrdU staining, the cells were
213 fixed with 4% paraformaldehyde, washed thrice with PBS, and treated with 2N HCL for 30min
214 and washed three times with PBS. Cells were incubated in 0.1% Triton X-100 in PBS for 20min
215 at 25°C and washed thrice with PBS. Then cells were blocked with 5% goat serum, treated with
216 Anti-BrdU antibody, and continued with the same immunofluorescence protocol described
217 above. Following imaging, BrdU positive cells were manually counted, and the percentage of
218 BrdU positive cells from the total population was calculated.

219 **Cell cycle analysis by Propidium Iodide staining**

220 For this assay, we used FxCycle™ PI/RNase Staining Solution (F10797, Invitrogen), which comes
221 with DNase-free RNase A and a permeabilization reagent to accurately stain the DNA content of
222 cells. Measuring the DNA content by flow cytometry is a standard method to understand various
223 phases of cell cycles in a given population. For this study, proliferating ReNcells were plated on a
224 6-well culture plate cultured for 24hr. Flow cytometry was carried out to analyze the cellular DNA
225 content. Fluorescence intensity of stained nuclei was measured with a flow cytometer (BD FACS
226 Calibur), and data were analyzed using FlowJo software.

227 **ROS analysis**

228 We measured Hydrogen peroxide, superoxide in differentiated cells using two methods. To
229 measure H₂O₂, we used AmplexRed Assay, where H₂O₂ reacts with Aplexred in the presence of
230 horseradish peroxidase (HRP) and forms the red fluorescent oxidation product Resourfin. 30,000
231 ReNcells were plated on a 96-well plate and differentiated into neurons and astrocytes. Cells were
232 treated with AmplexRed (50μM), HRP (0.2U) and incubated for 30min at 37°C. The resulting
233 fluorescence was measured using a fluorescent microplate reader at 530nm^{ex}/590nm^{em} (BioTek,
234 USA). Fluorescent readings were normalized to total protein. Similarly, we measured superoxide
235 using ROS-ID® Total ROS/Superoxide detection kit (Enzo Lifesciences). After plating, however,
236 cells were treated with 2μM superoxide detection reagent and incubated for 60min at 37°C in CO₂
237 incubator. Fluorescenc was measured at 550nm^{ex}/620nm^{em} (BioTek, USA) and normalized.

238 **Autophagy analysis in DF-HeLa cells**

239 Scr-Ctrl and TBCK KD DH-HeLA³¹ cells were cultured in DMEM with 10% FBS containing
240 Normocin (100μg/ml) and Zeocin (100μg/ml). For microscopy, 30,000 cells/well were plated on
241 chamber slides, cultured for 24hr, fixed with 4% PFA, then permeabilized with 0.1% Triton
242 X100 and stained with DAPI. For protein expression using western blot, 1x10⁶ cells were plated
243 on 60mm plates and total cell lysates were prepared using RIPA buffer. For induction of
244 autophagy, cells were treated overnight with 100nM rapamycin.

245 **Statistical analysis**

246 All experiments were performed in biological triplicates. Multiple comparisons were done using
247 one-way ANOVA followed by a Bonferroni's post-hoc test (Graph Pad PRISM). Student's t-test
248 was used to calculate statistical significance for comparing two groups (Graph Pad PRISM). A p-
249 value of less than 0.05 was considered significant (*p-value < 0.05, **p-value < 0.01, ***p-value
250 < 0.001). Error bars represent the mean ± standard error of the mean.

251 **Standard Protocol Approvals, Registrations, and Patient Consents**

252 This study does not include any human subjects research or animal models, there are no
253 recognizable persons included and not clinical trial data.

254

255 **Results:**

256 **mTORC1 activity varies in TBCK-knockdown ReNcells and patient-derived cells**

257 Children with TBCK syndrome show severe neurodegeneration leading to seizures,
258 neurologic decline, central respiratory insufficiency, and early death^{2, 4, 16}. To understand the
259 effects of loss of TBCK in neuronal differentiation and function *in vitro*, we used a human neural
260 progenitor cell line (ReNcell VM), which readily differentiated into neurons and astrocytes²². As
261 previously reported, ReNcells differentiate into neurons and astrocytes after culturing in N2/B27
262 medium without growth factors for two weeks (**Supplemental Figure. 1A**). To knockdown TBCK
263 using shRNA, we transiently transfected 293T cells with either the pLKO.1 non-targeting scramble
264 control (Scr-Ctrl) or one of five different shRNA that targeted different exons of the TBCK mRNA
265 (pLKO.1 TBCK sh1-sh5). We observed that sh4 and sh5 had the maximum knockdown efficiency
266 in 293T cells (**Supplementary Figure. 1B**). After confirming knockdown efficiency in 293T cells,
267 we transduced ReNcells with different dilutions of lentivirus carrying the pLKO.1 Scr-Ctrl or
268 pLKO.1 TBCK SH-5. Cells transduced with the TBCK SH-5 reduced TBCK mRNA levels in a
269 dose-independent manner (**Supplemental Figure. 1C**). Single-cell clones were isolated from
270 transduced cells, and qRT-PCR analysis indicated that most single-cell clones had knockdown
271 efficiency between 70-80% (**Figure. 1A & Supplementary Figure. 1D**). Single cell clones
272 (TBCK KD-sc1, TBCK KD-sc2) and single cell clone from Scr-Ctrl were used for further analysis.

273 Studies from patient-derived fibroblasts indicate that loss of TBCK inhibits mTORC1
274 activity² and increases accumulation of autophagosomes, illustrated by LC3 immunostaining¹⁶.
275 To investigate whether this is the case in NPC and neurons, we measured p-S6 and LC3 protein
276 levels in TBCK KD, ReNcells. Interestingly, knockdown of TBCK in proliferating and
277 differentiated ReNcells had no effect on phosphorylation of S6. However, we observed slightly
278 higher phosphorylation of S6 in two different TBCK knockdown sub clones (**Figure. 1B & C**).
279 LC3 levels were comparable to control in proliferating TBCK KD ReNcells (**Figure. 1B**), but we
280 observed higher LC3 in differentiated TBCK KD cells (**Figure. 1B & C**). When we directly
281 compared the mTORC1 activity between proliferating and differentiated ReNcells (**Supplemental**
282 **Figure. 1E**), we observed significantly lower mTORC1 activity in differentiated ReNcells
283 regardless of the genotype (pS6 as a proxy) in differentiated cells. Low mTORC1 activity in
284 differentiated cells may be a compounding factor for higher LC3 levels in TBCK KD differentiated
285 cells.

286 To tease out if these trends corresponded to other cell types, we used different clones of
287 TBCK knockdown DF-HeLa cells to look at p-S6 and LC3 levels (**Supplemental Figure. 1F**).
288 These HeLa cells express LC3 protein conjugated with GFP and RFP to differentiate
289 autophagosome vs autolysosome accumulation³¹. We observed no difference in p-S6 levels, but
290 there was a significant increase in LC3-II in different TBCK KD clones (**Figure. 1D &**
291 **Supplemental Figure. 1G**). Since TBCK knockdown in ReNcells and DF-HeLa did not inhibit
292 mTORC1 signaling, we analyzed p-S6 levels in patient-derived TBCK fibroblasts and
293 lymphoblasts (**Supplemental Table. 1**). Patient-derived TBCK lymphoblasts carrying different
294 pathogenic variants, there were no differences in p-S6 levels. Whereas dermal fibroblasts with the
295 homozygous loss of function mutation had low levels of both total S6 and p-S6 levels, indicating

296 total pathway reduction (**Figure. 1E & Supplemental Figure. 2A**). These results indicate that in
297 the absence of TBCK, mTORC1 signaling is not always downregulated. Instead, our results
298 suggest that mTORC1 activation is variable with reduced TBCK levels, and is a process heavily
299 modulated by cell type and mutation.

TBCK knockdown affects ReNcell differentiation into neurons and astrocytes

300 To understand the effects of TBCK knockdown on differentiation, Scr-Ctrl and TBCK KD
301 NPCs were differentiated into neurons and astrocytes (**Figure 2A**). After two weeks of
302 differentiation, TBCK KD neuronal somas had reduced cluster formation, and reduced neuronal
303 projections, as compared to the Scr-Ctrl cells, which showed cell aggregation indicated by
304 clustered somas with neuronal and glial projections in organized co-tract-like formations, as
305 observed by TUJ1 and GFAP staining (**Figure 2B, Supplemental Figure. 2B**). Similar results
306 were also observed in an additional TBCK KD monoclonal subpopulation (**Supplemental Figure.**
307 **2C**). Intensity of TUJ1, MAP2 and GFAP markers were also decreased in TBCK KD differentiated
308 cells (**Figure 2B, Supplemental Figure. 2D & E**), which accompanied significantly reduced
309 MAP2 and GFAP mRNA levels (**Figure. 2C**). Expression of a neural progenitor marker (PAX6)
310 appeared only in NPC and slightly elevated in TBCK KD cells at the proliferating stage, while the
311 neuronal maturation marker (MAP2) was significantly lower in TBCK KD cells at the
312 differentiated stage compared to Scr-Ctl (**Figure. 2D & Supplemental Figure. 2F**). Conversely,
313 we saw increased GFAP in differentiated TBCK KD cells (**Figure 2B, 2D & Supplemental**
314 **Figure 2F**). We stained differentiated ReNcells with another neuronal maturation marker, NeuN,
315 and found a significant reduction in the number of NeuN positive soma in TBCK KD cells (**Figure.**
316 **2E**). These results revealed that loss of TBCK delays or prevents neuronal differentiation and
317 maturation, in addition to neurite formation.

318
319 In addition to dysfunction of cortical neurons being implicated in intellectual disability,
320 TBCK patients also have motor impairment and many patients never achieve independent walking,
321 brain atrophy, corpus callosum dysgenesis, and cerebellar vermis hypoplasia ^{2,4}. Dopaminergic
322 (DA) neurons of the midbrain regulate voluntary movement, ³² and loss of these neurons is
323 associated with Parkinson's disease (PD) and Alzheimer's disease ^{33,34}. Since the degenerative
324 clinical symptoms in TBCK patients mimic other neurodegenerative diseases, we wanted to
325 investigate if TBCK also plays a role in the differentiation into TH-positive dopaminergic neurons.
326 Using TH as a marker, we observed not only a significant defect in the differentiation of DA
327 neurons but also a significant number of breaks along the length of neuronal extensions in these
328 cells (**Figure 2F & G**). Together with our cortical and DA neuron differentiation findings reveal
329 that knockdown of TBCK affects ReNcell differentiation into different neuronal subtypes.

330
331 **TBCK knockdown induced proliferation defects in NPCs and pro-apoptotic protein**
332 **induction during differentiation**

333 Due to the severe defects in TBCK KD ReNcells in NPC differentiation to neurons and
334 astrocytes, we wanted to understand the possible mechanism for this reduced differentiation. To
335 do this we investigated if cell proliferation was impacted and if cell death was induced. To
336 determine whether cell proliferation was affected, we stained proliferating cells with BrdU and
337 observed significantly fewer BrdU positive cells in TBCK KD cells (**Figure. 3A**). Further analyses

338 using a 3D neurosphere assay also showed proliferation defects in TBCK KD cells. While we
339 observed significant increases in neurosphere size in Scr-Ctrl cells, TBCK KD cells failed to grow
340 (**Figure. 3B & C**). Further assessment of the cell cycle profiles showed a higher number of cells
341 in the G0/G1 stage and fewer in the G2/M cell stage in the TBCK KD proliferating cells, indicative
342 of increased quiescent or senescence cells (**Figure. 3D**). Additionally, TBCK KD differentiated
343 cells showed reduced levels of anti-apoptotic marker, BCL-2, and higher levels of pro-apoptotic
344 markers BID, BAX and caspase-9 (**Figure 3E & Supplemental Figure. 3A & B**). While caspase-
345 3 levels were increased in differentiated cells irrespective of genotypes compared to proliferating
346 cells, we could not detect cleaved caspase-3 levels (**Figure. 3E & Supplemental Figure. 3B**).
347 These results indicate that TBCK knockdown affects cell cycles in the proliferating NPC cells and
348 induces apoptosis during differentiation.

349 350 **TBCK knockdown affects the transcriptome of proliferating and differentiated ReNcells**

351 We performed bulk RNA sequencing on both proliferating and differentiated TBCK KD
352 cells to understand the pathways affected at these two stages of neurodevelopment. PCA analysis
353 showed the difference between proliferating and differentiated cells on the principal component 1
354 (PC1) and a considerable difference between the Scr-Ctrl and TBCK KD groups on the PC2
355 (**Supplementary Figure. 3C**). We used NOISeq and DESeq2 pipelines to identify TBCK KD-
356 induced changes in gene expression profile (TBCK KD vs. Scr-Ctrl). Although TBCK KD had
357 lesser effect on the gene expression (73 genes significantly upregulated and 112 genes significantly
358 downregulated) in proliferating cells (**Figure. 4A & Supplementary Figure. 3D**), we observed a
359 sizeable number of differentially regulated transcripts in differentiated cells (1303 transcripts
360 significantly upregulated and 1072 transcripts significantly downregulated) (**Figure. 4B &**
361 **Supplementary Figure. 3D**). Overlapping of the TBCK KD-induced differentially regulated gene
362 transcript from proliferating and differentiated cells revealed that 42% of transcripts were
363 upregulated (47 out of 112) and 52% of downregulated (38 out of 73) (**Supplementary Figure.**
364 **3D**). We have presented all the genes and pathways significantly up or down regulated in the
365 proliferating and differentiated cells in **supplemental worksheet**. Our bulk RNAseq results
366 implicate inherent defects in NPCs that prevent proper differentiation into neural and glial
367 lineages. Additionally, this signifies that additional pathways are impacted by TBCK knockdown
368 after differentiation into neurons and astrocyte populations.

369 Therefore, we focused on differentiated ReNcells for gene ontology and pathway analysis
370 using GSEA. We observed several pathways to be significantly altered. Critical pathways that
371 significantly upregulated were ferroptosis, cholesterol and sterol biosynthesis, epithelial-
372 mesenchymal transition (EMT), and different mitochondrial pathways (**Figure. 4C**). There were
373 also a group of pathways associated with neuronal health, signaling and synapsis, and calcium and
374 potassium channels that were significantly downregulated (**Figure. 4C**). Beyond neuronal-specific
375 processes, ribosome and protein translation pathways were also downregulated. Increased
376 expression of several genes associated with EMT and ferroptosis pathways implicate that these
377 two pathways may play an essential role in the differentiation and cell survival defects we observed
378 (**Figure 4D & E**). Likewise, many mTORC1 signaling associated genes were significantly
379 upregulated in differentiated cells (**Figure. 4F**). Overall, these results show that many shared genes

380 are affected in TBCK KD proliferating and differentiated cells. Unsurprisingly, based on our
381 previous results, differentiated cells lacking TBCK have upregulation of several pathways
382 associated with neurodegeneration.

383 Since our bulk RNA-Seq analysis revealed ferroptosis induction during differentiation of
384 TBCK KD cells, we wanted to investigate if this was mediated by reactive oxygen species (ROS),
385 which play an essential role in the induction of ferroptosis ³⁵. We measured H₂O₂ and O₂⁻ and
386 observed that both were significantly increased in differentiated TBCK KD ReNcells (**Figure. 5A**
387 **& B**). To further validate upregulation of ferroptosis in differentiated TBCK KD ReNcells, we
388 measured a marker of ferroptosis, GPX4 ³⁵. Differentiated TBCK KD cells had significantly lower
389 levels of the GPX4 protein (**Figure. 5C & Supplemental Figure. 3E**), indicating that TBCK KD
390 increases ROS, initiates ferroptosis, and induces apoptosis programming leading to cell death in
391 TBCK KD differentiated cells.

392 **Differentiated TBCK KD cells show increased autophagy and accumulation of transport** 393 **markers in dead cells**

394 Although we found evidence to suggest apoptosis was being induced due to reduce TBCK
395 levels, the question as to how this was being mediated upstream remained. Therefore, we next
396 investigated the role of TBCK in neuronal autophagy. First, we stained Scr-Ctrl and TBCK KD
397 differentiated cells with a neuronal marker (TUJ1) and autophagy marker (LC3). We observed
398 accumulation of LC3-positive vesicles in the soma of TBCK KD cells compared to Scr-Ctrl
399 (**Figure. 5D & E**) and increased LC3-positive vesicles in neuronal projections of TBCK KD cells
400 (**Supplementary Figure. 3F**). In order to distinguish whether these LC3-positive vesicles were
401 autophagosomes or autolysosomes, we used a reporter line containing LC3-conjugated with GFP
402 and RFP (DF-HeLa). When autophagosomes fuse with the lysosomes, GFP is quenched inside the
403 lysosomes, while RFP remains stable (**Figure. 5F**). In TBCK KD DF-HeLa cells at baseline we
404 observed higher RFP vesicles compared to Scr-Ctrl (**Figure. 5G & H**) but GFP vesicles remained
405 the same (**Figure. 5H & Supplementary Figure. 3G**). When treated with rapamycin, a repressor
406 of mTOR signaling, we observed significantly higher RFP in TBCK KD cells compared to Scr-
407 Ctrl cells (**Figure. 5G, H & I**). We observed similar increases in LC3-II levels from western blot
408 analysis indicating accumulation of matured autophagosome accumulation. (**Figure. 5I &**
409 **Supplemental Figure. 4A**). These results implicate that autophagy induction is not affected in
410 TBCK KD DF-HeLa cells but the degradation of autophagosomes inside the lysosomes are
411 affected. In summary, loss of TBCK results in accumulation of autophagosomes in both ReNcell
412 neurons and DF-HeLa cells. Additionally, with the DF-HeLa we prove that the higher LC3 level
413 in TBCK KD cells is the result of incomplete degradation of autophagosomes inside the lysosomes.

414 Our bulk RNAseq analyses on differentiated cells indicated significant down-regulation
415 of genes that play an important role in synaptic transmission and axonal guidance (**Figure. 4C**).
416 Synapsin-1 plays an important role in nerve conduction at the axon terminals, so to understand the
417 distribution of Synapsin-1, we stained differentiated ReNcells with SYN1 and co-stained with
418 neurite marker (TUJ1). Surprisingly, we observed significantly higher numbers of Syn-1-positive
419 cells with fragmented nuclei in the TBCK KD differentiated cells, the latter indicating that they
420 were dead (**Figure. 6A & B**). Synapsin1 is produced in the soma and transported to axon terminals

421 in mature neurons³⁶. Presence of Syn-1-positive cells with fragmented nuclei implicates that either
422 SYN1 accumulates in the soma due to a lack of projections forming, or due to impaired axonal
423 transport leading to cell death.

424 To further understand if dead cells are positive for other organelles which are actively
425 transported across the neurons was also impaired due to TBCK knockdown, we stained for
426 lysosomes (LAMP1) and mitochondria (ATP5B). In TBCK KD differentiated cells, we observed
427 LAMP1+ and ATP5B+ cells with fragmented nuclei in significantly higher numbers (**Figure. 6C,**
428 **D, E & E1**). Therefore, we also investigated if the transport of vesicles was impacted, such as
429 early endosomal pathways that transport multiple cargoes including mRNAs for local protein
430 translation²⁰. We stained ReNcells for early endosomes (EEA1) and observed a decreased number
431 of endocytic vesicles per soma in TBCK KD cells, but a significant increase in their diameters
432 (**Figure. 6F & F1**). The presence of significantly larger vesicles implies fusion of multiple vesicles
433 due to accumulation in soma or improper transport. These results indicate that lack of TBCK
434 affects the distribution of different transport vesicles (early endosomes), organelles (lysosomes
435 and mitochondria) and cargo proteins (synapsin-1). Transport of cargo proteins, organelles, and
436 different proteins from soma to axon terminals, along the length of axons, play an essential role in
437 neuronal function³⁷. Therefore, our results suggests that excess accumulation of these cellular
438 components in soma stresses cells, impairing neuronal function and eventually leading to increased
439 ROS and cell death.

440 **TBCK knockdown alters mitochondrial quality in both proliferating and differentiated** 441 **ReNcells**

442 Anterograde and retrograde transport requires ATP, thus mitochondrial oxidative
443 phosphorylation and mitochondrial-health play a critical role in neuronal homeostasis³⁸. Previous
444 reports from TBCK patient fibroblast have compromised OXPHOS and mitochondrial biogenesis
445¹⁷. To investigate if there is increased mitochondrial stress in TBCK KD ReNcells, and to
446 determine readout mitochondrial function as an important readout for neurodegeneration, we
447 stained NPC and differentiated cells with mitotraker dye. Recent evidence that TBCK is part of
448 FERRY complex which carries number of mRNA that require for mitochondrial biogenesis²⁰,
449 further suggests role mitochondrial dysfunction in TBCK KD ReNcells. When stained
450 proliferating ReNcells with mitochondrial membrane-potential sensitive dye MitoTrackerTM
451 Orange CMTMRos, showed increased fragmentation and less dye accumulation in TBCK KD
452 cells (**Figure. 7A**). These results indicate that TBCK KD NPC have dysfunctional mitochondria.
453 Further, we stained differentiated cells with the mitochondria marker ATP5B and the neuronal
454 marker MAP2, and observed fewer mitochondria were present in the soma of TBCK KD neurons
455 (**Figure. 7B**). When we looked into the neuronal extensions, TBCK KD cells had overall less dense
456 mitochondria distribution (**Figure. 7C**). Additionally, we stained differentiated cells with
457 MitoTrackerTM Orange CMTMRos and found less dye accumulated in the soma (**Figure. 7D &**
458 **E**). Since we observed increased mitochondrial fragmentation in NPCs, we treated cells with
459 mitochondrial fission inhibitors Mdivi-1 and observed a significant increase in the dye
460 accumulation and improved mitochondrial network (**Figure. 7F & G**), suggesting a partial rescue

461 of this phenotype. These results indicate TBCK KD in ReNcells induces mitochondrial stress in
462 both proliferating and differentiated cells. Furthermore, these results reveal a potential cause for
463 cellular stress at NPC that leads to multiple cellular defects observed in differentiated TBCK KD
464 cells.

465 **Discussion:**

466 Individuals diagnosed with TBCK syndrome show severe neurodegeneration, as evidenced
467 by the progressive thinning of the corpus callosum and loss of brain volume observed in MRI scans
468 ^{2, 5, 16}. Many of these individuals exhibit progressive intellectual disability and seizures. However,
469 prior to this publication cell-culture-based studies exploring TBCK function were solely performed
470 in lymphoblasts or dermal fibroblasts. One recent study used iPSC derived NPC to understand the
471 role of TBCK in vesicle secretion, and while this important study lacked isogenic controls and
472 were not differentiated to neurons ²¹. To address whether loss of TBCK affects neurons, we
473 generated a knockdown model in the well-characterized human NPC cells ReNcell VM, to provide
474 insights into the role of TBCKs function in neurons. Our TBCK knockdown model revealed delays
475 in neuronal and astrocyte maturation, likely due to reduced proliferation and increased cell death
476 during or after differentiation. Our results are similar to Moreira et al., 2021 in that the NPC
477 proliferation was affected. Further, we show that mitochondrial defects and altered gene
478 expression in the proliferating NPC effected ReNcells differentiation into neurons and astrocytes.
479 Interestingly, we observed decreased MAP2 (neuronal maturation marker) and increased GFAP
480 (astrocyte marker). This could be due to either neurons dying or astrocytes over-proliferating.
481 Based on our cumulative results, we believe the former due to neuronal dependence on
482 mitochondrial oxidative phosphorylation, whereas astrocytes typically utilize glycolysis for their
483 energy demands. Moreover, elevated autophagosome accumulation observed in TBCK-deficient
484 neurons and astrocytes aligns with previous findings from TBCK patient fibroblasts ¹⁶. The
485 observed decrease in the total amount of differentiated neurons coupled with increased apoptosis
486 may indicate that individuals lacking functional copies of TBCK have a decreased capacity for
487 neurodifferentiation and neuronal maturation, thus leading to neurodevelopmental delay and
488 impaired neural function, and eventually neurodegeneration.

489 TBCK patients generally show phenotypes indicative of dysregulated function of the basal
490 ganglia neural circuitry, including speech delay, seizures, poor psychomotor and musculoskeletal
491 development ². Dopaminergic (DA) neurons regulate voluntary movement, motivation, and habit
492 learning as part of the basal ganglia circuitry in the midbrain ³². Their loss is associated with PD
493 and AD ^{33, 34}. When we differentiated ReNcells into DA neurons, the presence of fewer TH-
494 positive staining and more neuronal extensions were broken, indicative of defects in DA neuronal
495 function. These results are significant in that they suggest TBCK loss at NPC affects not only
496 general cortical neuronal differentiation but specialized neurons, such as DA neurons, as well.

497 With respect to the molecular function of TBCK, our data provide new insights into the the
498 role of mTORC1 in TBCK patients. Our current study varies from previous work showing
499 universally decreased mTORC1 activity or no differences in activity ²¹, indicating that variation in

500 signaling may exist between TBCK mutations, cell type, and growth factor presence. TBCK
501 knockdown in ReNcells moderately increased mTORC1 activity both in NPCs and completely
502 differentiated neurons. RNAseq results showed a number of mTORC1 signalling genes
503 significantly upregulated in TBCK KD neurons and astrocytes. In eukaryotes, mTORC1 regulates
504 cell growth and metabolism in response to nutrients, growth factors and stress. mTORC1
505 dysregulation is reported in AD/DS (Alzheimer's, Down's Syndrome), PD (Parkinson's), HD
506 (Huntington's) and ALS (Amyotrophic Lateral Sclerosis) both in the brain and peripheral cells ³⁹.
507 Researchers observed both hyperactivation and hypoactivation in these neurodegenerative
508 diseases, indicating that any dysregulation in mTORC1 affects brain function and viability.
509 Although we observed moderately higher levels of phosphorylation of ribosomal protein S6 in
510 TBCK KD ReNcells, future studies are required to fully understand how it may impact neuronal
511 differentiation.

512

513 With our RNAseq screen, we used a high-sensitivity unbiased approach to look at
514 comprehensive gene expression and uncovered several potential disease mechanisms by which
515 TBCK regulates autophagy, progenitor proliferation, and neuronal differentiation. As expected
516 based on our novel data, neuronal pathways were downregulated in ReNcells with targeted TBCK
517 knockdown, including nervous system development, synaptic transmission, axon guidance,
518 neurotransmitter receptor activity, neuron projections, postsynaptic density, glutamatergic and
519 cholinergic synapses, neurexins, and neuroligins. These aligned well with the clinical phenotypes
520 of seizures, brain atrophy, hypotonia, and respiratory deficiencies, supporting the hypothesis that
521 the systemic deficits are secondary to neurologic dysfunction ^{21, 40}. Interestingly, similar
522 neurodegenerative pathways associated with Huntington's disease were also up-regulated in
523 TBCK KD cells, further emphasizing these cells as a good model for neurodegeneration in
524 individuals with TBCK, and may also point to similar pathway dysregulation to those occurring in
525 Huntington's disease ⁴¹. On the other hand, epithelial-mesenchymal transition (EMT), a key
526 process in development and wound healing, was also found to be up-regulated, although it is often
527 associated with disease processes such as metastasis. In the context of TBCK, the significance of
528 EMT upregulation is less clear, as none of the individuals with TBCK have reported early detection
529 of cancer. However, these results could be pointing to a broader disruption in cell identity and
530 function. For example, it is possible that TBCK is needed for the proliferation and differentiation
531 of NPC during early stages of neurogenesis and thus contribute to neuronal apoptosis and axonal
532 instability in TBCK-deficient or -mutated circumstances.

533 Of particular interest is the observed mitochondrial dysfunction in our model. As ATP is
534 the primary energy sources for neurons, mitochondria play a critical role in supporting the high-
535 energy demands associated with cargo transport, lipid membrane maintenance, and synaptic
536 neurotransmission. Defects in mitochondrial function have previously been well documented to
537 lead to neurodegenerative diseases including Parkinson's Disease (PD), Alzheimer's Disease (AD),
538 and Amyotrophic Lateral Sclerosis ^{42, 43, 44}. Several mitochondria-related pathways have
539 previously been associated with cell stress, and were found to be up-regulated in our TBCK KD

540 cells. These included NO synthase regulation, ATP synthesis coupled with electron transport,
541 mitochondrial elongation and termination, glutathione metabolism, and oxidative phosphorylation.
542 As higher energetic demands are placed on cells, these pathways commonly are called upon to
543 help achieve cell homeostasis. Of particular note was the up-regulation of ferroptosis as well as
544 several biosynthetic processes related to lipid membrane metabolism. Ferroptosis is a unique form
545 of regulated cell death characterized by iron-dependent lipid peroxidation ⁴⁵ and showed
546 significant upregulation in TBCK knockdown cells. Abnormal regulation of ferroptosis has also
547 been implicated in a variety of diseases that have neurodegeneration, including Friedrich's Ataxia,
548 PD, AD, and Huntington's Disease (HD) ⁴⁶. Specifically, glutathione homeostasis is one of the
549 main metabolic pathways that regulate ferroptosis induction. If unchecked, ferroptosis can lead to
550 neuronal death, thus possibly contributing to the pathogenesis of neurodegeneration observed in
551 TBCK syndrome. Increased mitochondrial fragmentation and partial rescue with the mitochondrial
552 fission inhibitor mdivi1 suggests that TBCK is necessary for mitochondrial function. Mitochondrial
553 defects in NPCs, and improving mitochondrial dynamics with fission inhibitors implicate that this
554 pathway is a potential treatment modality to improve neuronal maturation and survival of these
555 cells.

556
557 The accumulation of autophagosomes and transport proteins seen in our TBCK-deficient
558 model may also be indicative of heightened cellular stress, leading to premature cell death and
559 defects in neuronal differentiation observed in our model. This is particularly relevant given that
560 various neurodegenerative diseases like PD, AD, HD, and ALS have specific mutated proteins that
561 accumulate causing cytotoxicity that contribute to disease pathogenesis ^{47, 48, 49}. Previous studies
562 of TBCK patient-derived fibroblasts have reported a higher accumulation of LC3 positive vesicles
563 that is likely due to incomplete degradation of autophagosomes inside the lysosomes ¹⁶. Our study
564 with HeLa cells expressing LC3 protein conjugated with GFP and RFP proved that lysosomal
565 degradation of autophagosomes is the primary reason for increased autophagy. While more
566 evidence is needed, these findings support TBCK's role as an important mediator for
567 mitochondrial homeostasis and autophagy.

568
569 Taken together, our findings indicate that NPC proliferation and neuronal maturation are
570 central to the pathogenesis in children with TBCK syndrome. Specifically, recent studies have
571 identified TBCK as a part of a multiprotein complex called the FERRY ^{20, 50}, which transport
572 mRNA to different parts of cell using RAB5 and early endosomal pathway. This cellular process
573 is essential in humans, who harbor long axonal tracts where local protein translation plays an
574 essential role in organelle biosynthesis. Therefore, the proposed TBCK FERRY complex likely
575 plays an essential role in neuronal health by supporting local protein translation in these axonal
576 tracts. While our studies support a function of TBCK in protein translation and transport, further
577 analyses are needed to determine whether or not these are direct causes of neurodegeneration.
578 Furthermore, our model reveals a severe reduction of neurite projection, likely impacting axonal
579 tract formation. We also observed dysregulation in the EEA1 distribution of the differentiated

580 cells, and when considered with Moreira et al.'s findings of aberrant Clathrin, initiation of
581 endocytosis may be considered for the role of the TBCK protein ²¹. Therefore, TBCK's role in
582 axonal transport may be secondarily important compared to other defects illustrated in our study.
583 TBCK syndrome is a severe and multi-organ dysfunction disease, and further studies are required
584 to understand the role of TBCK in different organ systems. Although we showed partial rescue
585 with the fission inhibitor, systemic studies using appropriate cell models are needed to fully
586 understand how this treatment can rescue transport dysfunction in other organ systems. In summary,
587 our ReNcell model of TBCK knockdown provides novel potential pathogenic cellular mechanisms
588 of disease, which open new avenues for therapeutic intervention both in early development and
589 postnatally.

590

591 **Acknowledgements:** Thank you to the Ortiz-Gonzalez laboratory at the Children's Hospital of
592 Philadelphia for sharing their TBCK patient-derived dermal fibroblast lines.

593 **Funding:** K08NS109281 to EJB

594

595 **References:**

- 596 1. Zapata-Aldana E, Kim DD, Remtulla S, Prasad C, Nguyen CT, Campbell C. Further delineation of
597 TBCK - Infantile hypotonia with psychomotor retardation and characteristic facies type 3. *Eur J*
598 *Med Genet* **62**, 273-277 (2019).
- 599 2. Bhoj EJ, *et al.* Mutations in TBCK, Encoding TBC1-Domain-Containing Kinase, Lead to a
600 Recognizable Syndrome of Intellectual Disability and Hypotonia. *Am J Hum Genet* **98**, 782-788
601 (2016).
- 602 3. Durham EL, *et al.* TBCK syndrome: a rare multi-organ neurodegenerative disease. *Trends Mol*
603 *Med*, (2023).
- 604 4. Beck-Wodl S, *et al.* Homozygous TBC1 domain-containing kinase (TBCK) mutation causes a
605 novel lysosomal storage disease - a new type of neuronal ceroid lipofuscinosis (CLN15)? *Acta*
606 *Neuropathol Commun* **6**, 145 (2018).
- 607 5. Chong JX, *et al.* Recessive Inactivating Mutations in TBCK, Encoding a Rab GTPase-Activating
608 Protein, Cause Severe Infantile Syndromic Encephalopathy. *Am J Hum Genet* **98**, 772-781 (2016).
- 609 6. Wu J, Lu G. Multiple functions of TBCK protein in neurodevelopment disorders and tumors. *Oncol*
610 *Lett* **21**, 17 (2021).
- 611 7. Pan X, Eathiraj S, Munson M, Lambright DG. TBC-domain GAPs for Rab GTPases accelerate
612 GTP hydrolysis by a dual-finger mechanism. *Nature* **442**, 303-306 (2006).
- 613 8. Stenmark H, Olkkonen VM. The Rab GTPase family. *Genome Biol* **2**, REVIEWS3007 (2001).
- 614 9. Veleri S, Punnakkal P, Dunbar GL, Maiti P. Molecular Insights into the Roles of Rab Proteins in
615 Intracellular Dynamics and Neurodegenerative Diseases. *Neuromolecular Med* **20**, 18-36 (2018).
- 616 10. Kiral FR, Kohrs FE, Jin EJ, Hiesinger PR. Rab GTPases and Membrane Trafficking in
617 Neurodegeneration. *Curr Biol* **28**, R471-R486 (2018).
- 618 11. Liu Y, Yan X, Zhou T. TBCK influences cell proliferation, cell size and mTOR signaling pathway.
619 *PLoS One* **8**, e71349 (2013).

- 620 12. Saxton RA, Sabatini DM. mTOR Signaling in Growth, Metabolism, and Disease. *Cell* **169**, 361-
621 371 (2017).
- 622 13. LiCausi F, Hartman NW. Role of mTOR Complexes in Neurogenesis. *Int J Mol Sci* **19**, (2018).
- 623 14. Lamming DW, Sabatini DM. A Central role for mTOR in lipid homeostasis. *Cell Metab* **18**, 465-
624 469 (2013).
- 625 15. Mao Z, Zhang W. Role of mTOR in Glucose and Lipid Metabolism. *Int J Mol Sci* **19**, (2018).
- 626 16. Ortiz-Gonzalez XR, *et al.* Homozygous boricua TBCK mutation causes neurodegeneration and
627 aberrant autophagy. *Ann Neurol* **83**, 153-165 (2018).
- 628 17. Tintos-Hernandez JA, Santana A, Keller KN, Ortiz-Gonzalez XR. Lysosomal dysfunction impairs
629 mitochondrial quality control and is associated with neurodegeneration in TBCK
630 encephaloneuronopathy. *Brain Commun* **3**, fcab215 (2021).
- 631 18. Rangaraju V, *et al.* Pleiotropic Mitochondria: The Influence of Mitochondria on Neuronal
632 Development and Disease. *J Neurosci* **39**, 8200-8208 (2019).
- 633 19. Kann O, Kovacs R. Mitochondria and neuronal activity. *Am J Physiol Cell Physiol* **292**, C641-657
634 (2007).
- 635 20. Schuhmacher JS, *et al.* The Rab5 effector FERRY links early endosomes with mRNA localization.
636 *Mol Cell* **83**, 1839-1855 e1813 (2023).
- 637 21. Moreira DP, *et al.* Neuroprogenitor Cells From Patients With TBCK Encephalopathy Suggest
638 Deregulation of Early Secretory Vesicle Transport. *Front Cell Neurosci* **15**, 803302 (2021).
- 639 22. Donato R, *et al.* Differential development of neuronal physiological responsiveness in two human
640 neural stem cell lines. *BMC Neurosci* **8**, 36 (2007).
- 641 23. Ortinou S, *et al.* Effect of 3D-scaffold formation on differentiation and survival in human neural
642 progenitor cells. *Biomed Eng Online* **9**, 70 (2010).
- 643 24. Bridges CR, *et al.* USP9X deubiquitylating enzyme maintains RAPTOR protein levels, mTORC1
644 signalling and proliferation in neural progenitors. *Sci Rep* **7**, 391 (2017).
- 645 25. Dobin A, *et al.* STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* **29**, 15-21 (2013).
- 646 26. Li B, Dewey CN. RSEM: accurate transcript quantification from RNA-Seq data with or without a
647 reference genome. *BMC Bioinformatics* **12**, 323 (2011).
- 648 27. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq
649 data with DESeq2. *Genome Biol* **15**, 550 (2014).
- 650 28. Tarazona S, Furió-Tarí P, Ferrer A, Conesa A. NOISeq: Differential Expression in RNA-seq.
651 *Version 216*, (2013).
- 652 29. Conway JR, Lex A, Gehlenborg N. UpSetR: an R package for the visualization of intersecting sets
653 and their properties. *Bioinformatics* **33**, 2938-2940 (2017).
- 654 30. Gu Z, Eils R, Schlesner M. Complex heatmaps reveal patterns and correlations in multidimensional
655 genomic data. *Bioinformatics* **32**, 2847-2849 (2016).
- 656 31. Loos B, du Toit A, Hofmeyr JH. Defining and measuring autophagosome flux-concept and reality.
657 *Autophagy* **10**, 2087-2096 (2014).

- 658 32. Luo SX, Huang EJ. Dopaminergic Neurons and Brain Reward Pathways: From Neurogenesis to
659 Circuit Assembly. *Am J Pathol* **186**, 478-488 (2016).
- 660 33. Surmeier DJ. Determinants of dopaminergic neuron loss in Parkinson's disease. *FEBS J* **285**, 3657-
661 3668 (2018).
- 662 34. Nobili A, *et al.* Dopamine neuronal loss contributes to memory and reward dysfunction in a model
663 of Alzheimer's disease. *Nat Commun* **8**, 14727 (2017).
- 664
- 665 35. Yang WS, Stockwell BR. Ferroptosis: Death by Lipid Peroxidation. *Trends Cell Biol* **26**, 165-176
666 (2016).
- 667 36. Hilfiker S, Pieribone VA, Czernik AJ, Kao HT, Augustine GJ, Greengard P. Synapsins as
668 regulators of neurotransmitter release. *Philos Trans R Soc Lond B Biol Sci* **354**, 269-279 (1999).
- 669 37. Sleigh JN, Rossor AM, Fellows AD, Tosolini AP, Schiavo G. Axonal transport and neurological
670 disease. *Nat Rev Neurol* **15**, 691-703 (2019).
- 671 38. Yellen G. Fueling thought: Management of glycolysis and oxidative phosphorylation in neuronal
672 metabolism. *J Cell Biol* **217**, 2235-2246 (2018).
- 673 39. Querfurth H, Lee HK. Mammalian/mechanistic target of rapamycin (mTOR) complexes in
674 neurodegeneration. *Mol Neurodegener* **16**, 44 (2021).
- 675 40. Murdock DR, *et al.* Transcriptome-directed analysis for Mendelian disease diagnosis overcomes
676 limitations of conventional genomic testing. *J Clin Invest* **131**, (2021).
- 677 41. Li S, Li XJ. Multiple pathways contribute to the pathogenesis of Huntington disease. *Mol*
678 *Neurodegener* **1**, 19 (2006).
- 679 42. Trigo D, Avelar C, Fernandes M, Sa J, da Cruz ESO. Mitochondria, energy, and metabolism in
680 neuronal health and disease. *FEBS Lett* **596**, 1095-1110 (2022).
- 681 43. Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases.
682 *Nature* **443**, 787-795 (2006).
- 683 44. Lin F, Luo SQ. Mitochondria in neurodegenerative diseases. *CNS Neurosci Ther* **25**, 813-815
684 (2019).
- 685 45. Maher P, Currais A, Schubert D. Using the Oxytosis/Ferroptosis Pathway to Understand and Treat
686 Age-Associated Neurodegenerative Diseases. *Cell Chem Biol* **27**, 1456-1471 (2020).
- 687 46. Kim SW, Kim Y, Kim SE, An JY. Ferroptosis-Related Genes in Neurodevelopment and Central
688 Nervous System. *Biology (Basel)* **10**, (2021).
- 689 47. Fleming A, *et al.* The different autophagy degradation pathways and neurodegeneration. *Neuron*
690 **110**, 935-966 (2022).
- 691 48. Corti O, Blomgren K, Poletti A, Beart PM. Autophagy in neurodegeneration: New insights
692 underpinning therapy for neurological diseases. *J Neurochem* **154**, 354-371 (2020).
- 693 49. Frake RA, Ricketts T, Menzies FM, Rubinsztein DC. Autophagy and neurodegeneration. *J Clin*
694 *Invest* **125**, 65-74 (2015).
- 695 50. Quentin D, *et al.* Structural basis of mRNA binding by the human FERRY Rab5 effector complex.
696 *Mol Cell* **83**, 1856-1871 e1859 (2023).

697

698 **Figure Legends:**

699 **Figure 1. TBCK knockdown in ReNcells do not down regulate mTORC1.**

700 **A:** qRT-PCR analysis of TBCK mRNA levels in lentivirus transduced single cell clones.

701 **B:** Representative Western blots of proliferating and differentiated ReNcells for Control, Scr-Ctrl, TBCK KD sc-1, and TBCK KD sc-2 for S6, p-S6, LC3, and Actin done in triplicate.

702 **C:** Band intensities were calculated in Image J normalized to Actin. The relative band intensity compared to control was presented. Error bars represent SEM. *vs. Scr-Ctrl.

703 **D:** Representative Western blots of Control and TBCK knockdown DF-HeLa cells for TBCK, S6, p-S6, LC3, and Actin done in triplicate.

704 **E:** Representative Western blots of controls and patient-derived lymphoblasts and fibroblast for S6, p-S6 and Actin done in triplicate.

709

710 **Figure 2. TBCK knockdown in ReNcells affected their neuronal and glial differentiation.**

711 **A:** Pictorial representation of ReNcell differentiation into neurons and astrocytes.

712 **B:** TUJ1, GFAP, and DAPI immunofluorescence staining for differentiated Scr-Ctrl and TBCK KD ReNcells done in triplicate. Images were taken at 20X magnification, scale bar represents 115.9 μ m.

713 **C:** qRT-PCR analysis of MAP2 and GFAP mRNA levels in differentiated Scr-Ctrl and TBCK KD ReNcells. Error bars represent SEM. *vs. Scr-Ctrl

714 **D:** Representative Western blots of proliferating and differentiated ReNcells for PAX6, MAP2, GFAP, and Actin done in triplicate.

715 **E:** Immunofluorescence staining of NeuN followed by counting the number of NeuN-positive cells in a given field. Data is the average of three experiments.

716 **F:** Immunofluorescence staining of Scr-Ctrl and TBCK KD ReNcells differentiated to dopaminergic neurons for Tyrosine Hydroxylase (TH) and DAPI. Images were taken at 20X magnification. The number of TH positive cells in a given field is presented as a graph. Scale bar is 10 μ m. Error bars represent SEM. *vs. Scr-Ctrl,

717 **G:** Enlarged image showing TH positive neuronal extensions. The percentage of broken extensions in a given field is presented as a graph. Scale bar is 50 μ m.

718 Error bars represent SEM. *vs. Scr-Ctrl

726

727 **Figure 3. TBCK knockdown affected cell proliferation in ReNcells.**

728 **A:** BrdU staining of proliferating Scr-Ctrl and TBCK KD ReNcells. Images were taken at 40X magnification. The number of BrdU-positive cells in a given field is counted and plotted as a percentage change. Data is the average of three experiments. Error bars represent SEM. *vs. Scr-Ctrl.

729 **B & C:** Equal-sized neurospheres are made in Aggrewell 800 plates, and size was calculated using Image J. Data is the average of three experiments. Error bars represent SEM. *vs. Scr-Ctrl.

730 **D:** Scr-Ctrl and TBCK KD proliferating ReNcells were stained with propidium iodide and cell cycle progression is analyzed by flow cytometry. Pictorial graph showing the proportion of cells in different phases of the cell cycle.

731 **E:** Representative Western blots of proliferating and differentiated ReNcells for BCL-2, BID, BAX, Caspase3, Caspase9, and Actin done in triplicate.

737

738 **Figure 4. RNASeq analysis of Scr-Ctrl and TBCK KD ReNcells revealed different pathways for neurodegeneration.**

739 **A:** MD plot of RNA-seq expression of 25,990 genes between Scr-Ctrl proliferating and TBCK KD proliferating cells. Red dots indicate differentially expressed genes that are upregulated in TBCK KD proliferating cells (Probability value > 0.9 and log₂ fold change > 0), while blue dots indicate differentially expressed genes that are downregulated in TBCK KD proliferating cells (Probability value > 0.9 and log₂ fold change < 0).

740 **B:** MA plot of RNA-seq expression of 57,736 genes between Scr-Ctrl differentiated and TBCK KD differentiated cells. Red dots indicate differentially expressed genes that are upregulated in TBCK KD differentiated cells (adjusted P value < 0.05 and log₂ fold change > 0), while blue dots indicate differentially expressed genes that are downregulated in TBCK KD differentiated cells (adjusted P value < 0.05 and log₂ fold change < 0).

747

748 **C:** GSEA was performed using different gene sets from Enrichr database with the significantly regulated genes from
749 differentiated cells (TBCK KD vs. Scr-Ctrl). Selected pathways from different gene sets (Biological Process, BP;
750 Cellular Component, CC; KEGG; Reactome) with adjusted P values ($p_{adj} < 0.05$) are shown. The shape represents the
751 source of different gene sets; color represents the direction of change; size represents the gene set size.
752 **D to F:** Heatmap representation of gene expression from selected pathways: **(D)** Epithelial Mesenchymal Transition,
753 MSigDB hallmark gene set; **(E)** Ferroptosis, KEGG; and **(F)** mTORC1 signaling, MSigDB hallmark gene set. Log-
754 transformed gene expression values are displayed as colors ranging from red to blue, as shown in the key. Red
755 represents an increase in gene expression, while blue represents a decrease in expression.

756
757 **Figure 5. Differentiated ReNcells with TBCK knockdown has increased ROS and autophagy.**

758 **A:** ROS measurements in RenCells differentiated into neurons and astrocytes by AmplexRed assay. Scr-Ctrl cells
759 were treated with 20 μ M hydrogen peroxide as a positive control. TBCK KD cells were treated with 5mM NAC as an
760 assay specific control. Error bars represent SEM. ***vs. Scr-Ctrl. ### vs. TBCK KD,
761 **B:** Superoxide levels in RenCells differentiated into neurons and astrocytes were measured using ROS-
762 ID[®] Superoxide detection reagent. Scr-Ctrl cells were treated with 50 μ M pyocyanin as a positive control. TBCK KD
763 cells were treated with 5mM NAC as an assay specific control. Error bars represent SEM. *vs. Scr-Ctrl.
764 **C:** Western blot quantifications of proliferating and differentiated ReNcells for GPX4 and Actin. Band intensities
765 were calculated using Image J normalized to Actin. The relative band intensity compared to control was presented.
766 Error bars represent SEM. ***vs. Scr-Ctrl
767 **D:** Immunofluorescence staining of LC3, TUJ1, and DAPI for differentiated Scr-Ctrl and TBCK KD ReNcells.
768 Images were taken at 63X magnification, scale bar = 9.2 μ m.
769 **E:** The fluorescence intensity of the soma region is plotted as a graph. Error bars represent SEM. ***vs. Scr-Ctrl.
770 **F:** Pictorial representation of DF-HeLa cells expressing LC3 conjugated with GFP and RFP. When autophagosomes
771 fuses with lysosomes, GFP is quenched, expressing only RFP conjugated LC3.
772 **G:** Scr-Ctrl and TBCK KD DF-HeLA cells treated with rapamycin and accumulation of GFP and RFP puncta were
773 imaged at 63X magnification, scale bar = 24.6 μ m.
774 **H:** The RFP intensities of the cells were calculated using image J and expressed as corrected total cell fluorescence
775 (CTCF). Error bars represent SEM. *** vs. Scr-Ctrl.
776 **I:** Representative Western blots of Scr-Ctrl and TBCK KD DF-HeLa treated with 100nM Rapamycin for S6, pS6,
777 LC3 and Actin done in triplicate.
778 All the immunofluorescence images represent three independent experiments.

779
780 **Figure 6. TBCK KD differentiated ReNcells accumulated dead cells staining for different**
781 **transport proteins.**

782 **A & B:** **(A)** Immunofluorescence staining of SYN1, TUJ1, and DAPI for differentiated Scr-Ctrl and TBCK KD
783 ReNcells. Images were taken at 63X magnification, scale bar = 7 μ m. **(B)** The number of dead cells and dead cells
784 positive for SYN1 is presented as a graph. Error bars represent SEM. *** vs. Scr-Ctrl.
785 **C & D:** **(C)** Immunofluorescence staining of LAMP1 and DAPI for differentiated Scr-Ctrl and TBCK KD ReNcells.
786 Images were taken at 63X magnification, scale bar = 7 μ m. **(D)** The number of dead cells positive for LAMP1 is
787 presented as a graph. Data represent an average of three experiments. Error bars represent SEM. *** vs. Scr-Ctrl.
788 **E:** Immunofluorescence staining of ATP5B, MAP2, and DAPI for differentiated Scr-Ctrl and TBCK KD ReNcells.
789 Images were taken at 63X magnification, scale bar = 36.8 μ m. Panels on the right show equally zoomed in views of
790 panels on the left outlined in dashed-white boxes. White arrows denote accumulated ATP5B. **(E1)** The number of
791 dead cells positive for ATP5B is presented as a graph. Error bars represent SEM. *** vs. Scr-Ctrl
792 **F:** Immunofluorescence staining of EEA1, TUJ1, and DAPI for differentiated Scr-Ctrl and TBCK KD ReNcells.
793 Images were taken at 63X magnification, scale bar = 50 μ m. **(F1)** Average number of vesicles in the soma and the
794 average diameter of the vesicles are presented as a graph. Error bars represent SEM. *** vs. Scr-Ctrl.
795 All the immunofluorescence images represent three independent experiments.

796
797 **Figure 7. TBCK KD in ReNcells affected mitochondrial quality.**

798 **A:** Scr-Ctrl and TBCK KD proliferating ReNcells were treated with MitoTracker[™] Orange CMTMRos and DAPI.
799 Panels on the right show equally zoomed in views of panels on the left outlined in dashed-white boxes. Scale bar is
800 26.3 μ m. The fluorescence intensity of each cell is presented as CTCF. Error bars represent SEM. *** vs. Scr-Ctrl.

801 **B & C: (B)** Immunofluorescence staining of ATP5B, MAP2, and DAPI for differentiated Scr-Ctrl and TBCK KD
802 ReNcells. Panels on the right show equally zoomed in views of panels on the left outlined in dashed-white boxes.
803 Images were taken at 100X magnification, scale bar is 9.2 μ m. **(C)** Enlarged images focused at neuronal extensions
804 from Scr-Ctrl and TBCK KD cells were presented.
805 **D:** Scr-Ctrl and TBCK KD differentiated ReNcells were treated with MitoTracker™ Orange CMTMRos and counter
806 stained for TUJ1 and DAPI. Scale bar is 9.2 μ m.
807 **E:** Scr-Ctrl and TBCK KD differentiated cells treated MitoTracker™ Orange CMTMRos and DAPI. The fluorescence
808 intensity of each cell is presented as CTCF. Error bars represent SEM. ***vs. Control.
809 **F:** TBCK KD proliferating ReNcells treated with Mdivi-1 shows rescue of MitoTracker™ Orange phenotype loss
810 observed in KD cells. Scale bar is 14.7 μ m.
811 **G:** Quantification of Panel F showing significant decrease of MitoTracker™ Orange in TBCK KD cells and significant
812 increase in TBCK KD cells after treatment with Mdivi-1. The fluorescence intensity of each cell is presented as CTCF.
813 Error bars represent SEM. ***vs. Control, #vs. Mdivi-1.

Figure.1




Figure.2




Figure.3






Figure.4








Figure.7

